Of course it does, it’s not had British involvement in its development.
The inferior Oxford vaccine not only gives an impressive level of protection for up to 12 weeks, it’s also very effective at reducing transmission. And that’s after just one jab.
It looks like the one dose to as many people as possible strategy is another winner against this virus.
Covid-19: Study showing Oxford vaccine slows virus spread 'superb' - Hancock
https://www.bbc.co.uk/news/uk-55913913
That study is written by collaborators in the AZ vaccine and the study is still not published.
We only have their summary findings, no data as such.
You can read it here:
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268
From the study, after 12 weeks, the antibodies GMR drops to 66% of the level of 6 weeks, and yet, our government and the BBC still claim that the protection remains same.
As for the transmission reduction, the summary did not say what the finding was based on.
I think Matt Hancock is becoming a bit Bojo-esque nowadays.
QUOTE:
Findings: 17,177 baseline seronegative trial participants were eligible for inclusion in the efficacy analysis, 8948 in the UK, 6753 in Brazil and 1476 in South Africa, with 619 documented NAAT +ve infections of which 332 met the primary endpoint of symptomatic infection >14 days post dose 2.The primary analysis of overall vaccine efficacy >14 days after the second dose including LD/SD and SD/SD groups, based on the prespecified criteria was 66.7% (57.4%, 74.0%). There were no hospitalisations in the ChAdOx1 nCoV-19 group after the initial 21 day exclusion period, and 15 in the control group.Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 post vaccination was 76% (59%, 86%), and modelled analysis indicated that protection did not wane during this initial 3 month period. Similarly, antibody levels were maintained during this period with minimal waning by day 90 day (GMR 0.66, 95% CI 0.59, 0.74).In the SD/SD group, after the second dose, efficacy was higher with a longer prime-boost interval: VE 82.4% 95%CI 62.7%, 91.7% at 12+ weeks, compared with VE 54.9%, 95%CI 32.7%, 69.7% at <6 weeks. These observations are supported by immunogenicity data which showed binding antibody responses more than 2-fold higher after an interval of 12 or more weeks compared with and interval of less than 6 weeks GMR 2.19 (2.12, 2.26) in those who were 18-55 years of age.